MDM2 amplification in malignant peripheral nerve sheath tumors correlates with p53 protein expression

Archives of Pathology and Laboratory Medicine

Volumn 136, Issue 1, 2012, Pages 95-99

  Wallander, Michelle L ^a   Tripp, Sheryl ^a   Layfield, Lester J ^b  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; MDM2 PROTEIN, HUMAN; MIB 1 ANTIBODY; MIB-1 ANTIBODY; MONOCLONAL ANTIBODY; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER;

ARTICLE; CELL PROLIFERATION; COMPARATIVE STUDY; DIFFERENTIAL DIAGNOSIS; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENETICS; HUMAN; METABOLISM; MUTATION; NERVE SHEATH TUMOR; NEURILEMOMA; NEUROFIBROMA; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY;

ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL; CELL PROLIFERATION; DIAGNOSIS, DIFFERENTIAL; GENE AMPLIFICATION; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; NERVE SHEATH NEOPLASMS; NEURILEMMOMA; NEUROFIBROMA; PROTO-ONCOGENE PROTEINS C-MDM2; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84856052197     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2010-0729-OA     Document Type: Article

References (9)

1. Momand J, Jung D, Wilczynski S, Niland J. The MDM2 gene amplification database. Nucleic Acids Res. 1998;26(15):3453-3459. (Pubitemid 28347214)
2. Hostein I, Pelmus M, Aurias A, Pedeutour F, Mathoulin-Pélissier S, Coindre JM. Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J Pathol. 2004;202(1):95-102. (Pubitemid 38072850)
3. Binh MB, Sastre-Garau X, Guillou L, et al. MDM2 and CDK4 immunostainings are useful adjuncts in diagnosing well-differentiated and dedifferentiated liposarcoma subtypes: a comparative analysis of 559 soft tissue neoplasms with genetic data. Am J Surg Pathol. 2005;29(10):1340-1347. (Pubitemid 41368770)
4. Kindblom LG, Ahldén M, Meis-Kindblom JM, Stenman G. Immunohistochemical and molecular analysis of p53, MDM2, proliferating cell nuclear antigen and Ki67 in benign and malignant peripheral nerve sheath tumours. Virchows Arch. 1995;427(1):19-26.
5. Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status. J Natl Cancer Inst. 1994;86(17):1297-302. (Pubitemid 24276791)
6. Szadowska A, Olborski B, Harezga-Bal B, Debiec-Rychter M. Expression of P53,MDM2 and Ki-67 antigens in soft tissue sarcomas. Pol J Pathol. 1999;50(1):9-16. (Pubitemid 29234807)
7. Watanabe T, Oda Y, Tamiya S, Kinukawa N, Masuda K, Tsuneyoshi M. Malignant peripheral nerve sheath tumours: high Ki67 labeling index is the significant prognostic indicator. Histopathology. 2001;39(2):187-197. (Pubitemid 34225046)
8. Würl P, Taubert H, Bache M, et al. Frequent occurrence of p53 mutations in rhabdomyosarcoma and leiomyosarcoma, but not in fibrosarcoma and malignant neural tumors. Int J Cancer. 1996;69(4):317-323. (Pubitemid 26298298)
9. Tanas MR, Rubin BP, Tubbs RR, Billings SD, Downs-Kelly E, Goldblum JR. Utilization of fluorescence in situ hybridization in the diagnosis of 230 mesenchymal neoplasms: an institutional experience. Arch Pathol Lab Med. 2010;134(12):1797-1803.